A carregar...
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
BACKGROUND: We report a subgroup analysis of afatinib with respect to its efficacy, safety, and the long‐term survival of patients in a Named Patient Use program at a single institution. METHODS: We analyzed 60 patients with stage IV non‐small cell lung cancer (NSCLC) who had been treated with ≥1 li...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8107028/ https://ncbi.nlm.nih.gov/pubmed/33811467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13957 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|